BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17266026)

  • 21. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ.
    Miller FR; Santner SJ; Tait L; Dawson PJ
    J Natl Cancer Inst; 2000 Jul; 92(14):1185-6. PubMed ID: 10904098
    [No Abstract]   [Full Text] [Related]  

  • 22. IL-6-mediated cross-talk between human preadipocytes and ductal carcinoma in situ in breast cancer progression.
    Kim HS; Jung M; Choi SK; Woo J; Piao YJ; Hwang EH; Kim H; Kim SJ; Moon WK
    J Exp Clin Cancer Res; 2018 Aug; 37(1):200. PubMed ID: 30134951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.
    Van Bockstal M; Lambein K; Gevaert O; De Wever O; Praet M; Cocquyt V; Van den Broecke R; Braems G; Denys H; Libbrecht L
    Histopathology; 2013 Oct; 63(4):520-33. PubMed ID: 23889174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy.
    Hong Y; Limback D; Elsarraj HS; Harper H; Haines H; Hansford H; Ricci M; Kaufman C; Wedlock E; Xu M; Zhang J; May L; Cusick T; Inciardi M; Redick M; Gatewood J; Winblad O; Aripoli A; Huppe A; Balanoff C; Wagner JL; Amin AL; Larson KE; Ricci L; Tawfik O; Razek H; Meierotto RO; Madan R; Godwin AK; Thompson J; Hilsenbeck SG; Futreal A; Thompson A; Hwang ES; Fan F; Behbod F;
    J Pathol; 2022 Feb; 256(2):186-201. PubMed ID: 34714554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of laminin-5 in the epithelium-stroma interface: an immunohistochemical marker of malignancy in epithelial lesions of the breast.
    Henning K; Berndt A; Katenkamp D; Kosmehl H
    Histopathology; 1999 Apr; 34(4):305-9. PubMed ID: 10231397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myoepithelial cell differentiation markers in ductal carcinoma in situ progression.
    Russell TD; Jindal S; Agunbiade S; Gao D; Troxell M; Borges VF; Schedin P
    Am J Pathol; 2015 Nov; 185(11):3076-89. PubMed ID: 26343330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
    Nielsen BS; Rank F; Illemann M; Lund LR; Danø K
    Int J Cancer; 2007 May; 120(10):2086-95. PubMed ID: 17290405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical study of TGF-alpha, TGF-beta1, EGFR, and IGF-1 expression in human breast carcinoma.
    Pilichowska M; Kimura N; Fujiwara H; Nagura H
    Mod Pathol; 1997 Oct; 10(10):969-75. PubMed ID: 9346175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cytoplasmic expression of aquaporin-1 in breast cancer cells and its relationship with clinicopathological characteristics and prognosis].
    Zhang B; Liu FF; Ma YJ; Gu F
    Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):904-9. PubMed ID: 24506959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of CD 44 s, CD 44 v 3 and CD 44 v 6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan.
    Auvinen P; Tammi R; Tammi M; Johansson R; Kosma VM
    Histopathology; 2005 Oct; 47(4):420-8. PubMed ID: 16178897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
    Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
    Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of proteoglycan versican in in situ breast lesions: relations between stromal changes, histotype, and invasion.
    Canavese G; Candelaresi G; Castellano I; Mano MP
    Pathol Res Pract; 2011 Feb; 207(2):97-103. PubMed ID: 21185131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis.
    Moinfar F; Man YG; Arnould L; Bratthauer GL; Ratschek M; Tavassoli FA
    Cancer Res; 2000 May; 60(9):2562-6. PubMed ID: 10811140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SMARCE1 is required for the invasive progression of in situ cancers.
    Sokol ES; Feng YX; Jin DX; Tizabi MD; Miller DH; Cohen MA; Sanduja S; Reinhardt F; Pandey J; Superville DA; Jaenisch R; Gupta PB
    Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4153-4158. PubMed ID: 28377514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium.
    Ao M; Franco OE; Park D; Raman D; Williams K; Hayward SW
    Cancer Res; 2007 May; 67(9):4244-53. PubMed ID: 17483336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression.
    Logullo AF; Nonogaki S; Pasini FS; Osório CA; Soares FA; Brentani MM
    Oncol Rep; 2010 Feb; 23(2):313-20. PubMed ID: 20043090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increase of GKLF messenger RNA and protein expression during progression of breast cancer.
    Foster KW; Frost AR; McKie-Bell P; Lin CY; Engler JA; Grizzle WE; Ruppert JM
    Cancer Res; 2000 Nov; 60(22):6488-95. PubMed ID: 11103818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.